Protecting Consumer Access to Generic Drugs Act of 2026
Key claim: A House bill meant to protect consumer access to generic drugs has been introduced and sent to the Energy and Commerce and Judiciary committees for consideration.
Abstract
(HR10887 · 119th Congress) Latest action (2026-10-22): Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Why this matters
Generic competition is one of the main downward pressures on U.S. drug prices, and bills referred jointly to Energy and Commerce and Judiciary typically touch patent, antitrust, or pay-for-delay practices that can slow generic entry. At the introduction stage, however, there is no scored mechanism or committee action, so the finding sits alongside other early-stage generic-access vehicles in the drug-pricing area without yet changing what patients pay.